NCT05041101 2025-06-13
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT03658772 2023-10-24
Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
Arrys Therapeutics
Phase 1 Completed
NCT03696212 2021-02-21
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Arrys Therapeutics
Phase 1/2 Terminated
NCT02538432 2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
Phase 2 Withdrawn